Better Together: Targeted Combination Therapies in Breast Cancer

摘要: Recent discoveries both in cell proliferation and survival mechanisms new antineoplastic agents have led to deep change the breast cancer treatment paradigm. Nonetheless, all of progress knowledge strategy has not been enough overcome escape resistance put place by tumor cells. New targeted mean possibilities for combinations, a viable option try stop compensatory pathways growth activated response therapeutics. The main challenges designing combined therapy come from variety subtypes (luminal A, luminal B, HER2-enriched, basal-like) multitude each subtype can exploit. research focused on dual blockade HER2 (trastuzumab-lapatinib; trastuzumab-pertuzumab) concomitant endocrine driver other such as PI3K/AKT/mTOR pathway (everolimus-exemestane), (trastuzumab/lapatinib-endocrine therapy) cycle through cyclin-dependent kinase inhibition (letrozole-palbociclib). This personalized approach needs profound leading subtype. Deepening our understanding is mandatory keep improving efficacy combination therapy.